BofA analyst Travis Steed initiated coverage of Kestra Medical (KMTS) with a Buy rating and $30 price target Kestra’s ASSURE product, a wearable cardioverter defibrillator that helps protect people at elevated risk of sudden cardiac arrest, offers “numerous improvements” over the incumbent Zoll Medical (ZOLL) WCD, the analyst tells investors. The firm thinks Kestra will be able to take market share from Zoll Medical in the established $1B U.S. WCD market and expand the market, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies: Positioned for Growth in the Wearable Cardioverter Defibrillator Market
- Kestra Medical initiated with an Outperform at Wolfe Research
- Kestra Medical initiated with an Overweight at Wells Fargo
- Kestra Medical initiated with a Buy at Stifel
- Kestra Medical initiated with an Overweight at Piper Sandler